Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

Published:2014-06-13 Issue:17 Volume:120 Page:2657-2664
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kaufman Peter A.¹,Bloom Kenneth J.²,Burris Howard³⁴,Gralow Julie R.⁵⁶,Mayer Musa⁷,Pegram Mark⁸,Rugo Hope S.⁹,Swain Sandra M.¹⁰,Yardley Denise A.³⁴,Chau Miu¹¹,Lalla Deepa¹¹,Yoo Bongin¹¹,Brammer Melissa G.¹¹,Vogel Charles L.¹²

Affiliation:

1. Dartmouth‐Hitchcock Medical CenterLebanon New Hampshire

2. Clarient, Inc.Aliso Viejo California

3. Sarah Cannon Research InstituteNashville Tennessee

4. Tennessee OncologyNashville Tennessee

5. University of Washington Medical OncologySeattle Washington

6. Seattle Cancer Care AllianceSeattle Washington

7. Patient AdvocateNew York New York

8. Stanford Cancer Institute, Stanford University School of MedicineStanford California

9. University of California San Francisco Comprehensive Cancer CenterSan Francisco California

10. Washington Cancer InstituteWashington DC

11. Genentech, Inc.South San Francisco California

12. Sylvester Comprehensive Center at Deerfield, Miller School of Medicine, University of MiamiDeerfield Beach Florida

Funder

Genentech

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.28710

Reference33 articles.

1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

2. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

3. HER2-Positive Breast Cancer

4. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

5. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes;The Breast;2024-02

2. Machine learning‐based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results;Cancer Medicine;2024-01-17

3. Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry;Annals of Surgical Oncology;2023-11-07

4. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer;Annals of Oncology;2023-08

5. Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies;JCO Precision Oncology;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3